



(11) **EP 3 636 781 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 54

(51) Int Cl.:
C12Q 1/70 (2006.01) A61K 31/00 (2006.01)

(48) Corrigendum issued on:
17.06.2020 Bulletin 2020/25

(43) Date of publication:
15.04.2020 Bulletin 2020/16

(21) Application number: **18199748.7**

(22) Date of filing: **10.10.2018**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(72) Inventors:
• **Altfeld, Marcus**
20251 Hamburg (DE)
• **Martrus Zapater, Glòria**
20251 Hamburg (DE)

(74) Representative: **Uexküll & Stolberg**
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg (DE)

(71) Applicant: **Heinrich-Pette-Institut Leibniz-Institut**
für
Experimentelle Virologie
20251 Hamburg (DE)

(54) **NOVEL SCREENING ASSAYS FOR IDENTIFYING COMPOUNDS REVERSING HIV-1 LATENCY**

(57) The present invention relates to a method for identifying compounds which reverse HIV-1 latency in a subject and can therefore be therapeutically used for eliminating a latent viral reservoir in a subject infected with HIV-1. Further, the present invention relates to a method for identifying compounds which stabilize HIV-1 latency in a subject and can therefore be therapeutically used for preventing replication and outgrowth of latent HIV-1. In yet another aspect, the present invention relates to a compound that increases or decreases the expression level of the HIV-1 Vpu gene for use in method of treating an HIV-1 infection in a subject in need thereof. In yet another aspect, the present invention relates to a compound that increases or decreases the binding between the HIV-1 Vpu protein and NF- κ B for use in method of treating an HIV-1 infection in a subject in need thereof.

A.




Fig. 7